At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 471 enrolled
Drug / intervention
IPX066 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease
In Brief
A Phase 3 clinical trial evaluating IPX066 and IR CD-LD for Parkinson's Disease. Completed, enrolled 471 participants across 73 sites in 8 countries.
Detailed Summary
This is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesCanada, France, Germany, Poland, Romania, Spain, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2009
First PostedSep 2009
Primary CompletionJan 2011
Study CompletionMar 2011
TodayJul 2026
First PostedSep 11, 2009
Enrollment StartSep 1, 2009
Primary CompletionJan 1, 2011
Study CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.8 years ago
Interventions
IPX066drug
extended-release carbidopa-levodopa capsules
IR CD-LDdrug
immediate-release carbidopa-levodopa tablets